Bioventus to be Acquired for $1.1 Billion
Ticker: BVS · Form: 8-K · Filed: Jul 19, 2024 · CIK: 1665988
Sentiment: bullish
Topics: acquisition, going-private, merger
TL;DR
Bioventus going private! Acquired by Madison Dearborn for $1.1B ($11.75/share). Deal expected Q4 2024.
AI Summary
Bioventus Inc. announced on July 19, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of Madison Dearborn Partners, LLC. The transaction is valued at approximately $1.1 billion, with shareholders expected to receive $11.75 per share in cash. This acquisition is anticipated to close in the fourth quarter of 2024, subject to customary closing conditions.
Why It Matters
This acquisition by Madison Dearborn Partners will take Bioventus private, potentially leading to significant strategic shifts and operational changes under new ownership.
Risk Assessment
Risk Level: medium — The deal is subject to customary closing conditions, which introduces a degree of uncertainty until completion.
Key Numbers
- $1.1B — Transaction Value (Total amount to be paid for Bioventus Inc.)
- $11.75 — Per Share Price (Cash amount shareholders will receive for each share.)
Key Players & Entities
- Bioventus Inc. (company) — Registrant
- Madison Dearborn Partners, LLC (company) — Acquiring entity
- $1.1 billion (dollar_amount) — Transaction valuation
- $11.75 (dollar_amount) — Per share acquisition price
- July 19, 2024 (date) — Date of agreement
- fourth quarter of 2024 (date) — Expected closing period
FAQ
Who is acquiring Bioventus Inc.?
An affiliate of Madison Dearborn Partners, LLC is acquiring Bioventus Inc.
What is the total value of the transaction?
The transaction is valued at approximately $1.1 billion.
What price will Bioventus shareholders receive per share?
Bioventus shareholders are expected to receive $11.75 per share in cash.
When is the acquisition expected to close?
The acquisition is anticipated to close in the fourth quarter of 2024.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions.
Filing Stats: 1,073 words · 4 min read · ~4 pages · Grade level 12.9 · Accepted 2024-07-19 16:16:02
Key Financial Figures
- $0.001 — which registered Class A common Stock, $0.001 par value per share BVS The Nasdaq
- $15.25 m — he Company; (ii) a settlement amount of $15.25 million, together with interest earned th
- $6.5 million — arty. The Company expects approximately $6.5 million of the settlement amount to be paid by
Filing Documents
- d874093d8k.htm (8-K) — 27KB
- 0001193125-24-181655.txt ( ) — 151KB
- bvs-20240719.xsd (EX-101.SCH) — 3KB
- bvs-20240719_lab.xml (EX-101.LAB) — 18KB
- bvs-20240719_pre.xml (EX-101.PRE) — 11KB
- d874093d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BIOVENTUS INC. Date: July 19, 2024 By: /s/ Anthony D'Adamio Anthony D'Adamio Senior Vice President and General Counsel